Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Journal article
Datoo MS. et al, (2024), Lancet (London, England), 403, 533 - 544
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Journal article
Schmit N. et al, (2024), The Lancet. Infectious diseases
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
Journal article
Venkatraman N. et al, (2019), The Journal of Infectious Diseases, 219, 1187 - 1197
"PRIME-TARGET" IMMUNIZATION WITH VIRAL VECTORS FOR ENHANCED EFFICACY OF LIVER-STAGE MALARIA VACCINES
Conference paper
Ewer K. et al, (2018), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 99, 585 - 585
EFFICACY OF THE NOVEL PLASMODIUM FALCIPARUM BLOOD-STAGE VACCINE RH5.1/AS01B IN A PHASE I/IIA CLINICAL TRIAL
Conference paper
Minassian A. et al, (2018), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 99, 581 - 582